SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Novo Nordisk - ADR

Novo Nordisk A/S

Novo Nordisk is trending as the community discusses the implications of the company's recent Phase III trial failure for its Alzheimer's drug, with some investors expressing disappointment while others see it as an opportunity to buy. Despite the setback, there is optimism surrounding Novo Nordisk's position in the weight loss market, particularly with the potential upcoming approval of its oral Wegovy pill and comparison of CagriSema vs Zepbound study results.

Pony.ai, Inc. develops artificial intelligence-based robot designed for autonomous driving. The firm's software algorithms and infrastructure enables a vehicle to perceive its surroundings, predict what others will do, and maneuver itself accordingly. The company was founded by Jun Peng and Tian Cheng Lou in November 4, 2016 and is headquartered in Guangzhou, China.

Pony AI Inc. - ADR

Pony AI Inc

Pony AI is trending due to news of expanded robotaxi operations and partnerships, including a recent permit in Shanghai. The community is weighing the company's growth prospects against its financial performance, especially regarding profitability targets. Broader discussions involve comparing Pony AI to competitors in the autonomous driving space and assessing the impact of these developments on its market position.

Diginex Ltd. (Hong Kong) is a blockchain financial services and technology company. Its products include diginexESG, diginexLUMEN, diginexAPPRISE, diginexLUMEN Pro, and CSRD framework. The company was founded by Miles Christian Pelham on May 15, 2020 and is headquartered in London, the United Kingdom.

Diginex Ltd.

DGNX is trending due to its recent acquisition of The Remedy Project, sparking discussions about the company's expansion into human-rights remediation. The community is also actively analyzing potential trading strategies based on historical patterns of similar stocks. Options traders are closely monitoring put contracts, anticipating potential downside amidst the volatility.

WeRide, Inc. operates as an investment holding company. It engages in the sale of autonomous driving vehicles, primarily including robobuses, robotaxis, robosweepers and related sensor suites. The company was founded by Tony Xu Han and Yan Li in February 2017 and is headquartered in Guangzhou, China.

WeRide Inc. - ADR

WeRide is trending due to strong Q3 2025 earnings, highlighted by a 144.3% YoY revenue increase and significant growth in robotaxi revenue, with community members noting global expansion and regulatory milestones in the UAE and Switzerland. Investors are focused on WeRide's progress toward deploying hundreds of thousands of robotaxis by 2030 and its partnerships with companies like Bosch, Uber, and Grab. The conversation also includes comparisons to competitor Pony.ai, whose stock performance and institutional ownership are being weighed against WeRide's recent gains and expansion efforts.

Monad

Monad is trending as users discuss its upcoming launch and token distribution, particularly excitement around receiving tokens from the Coinbase presale. The community is actively speculating on potential price movements and strategies, with some comparing it to other recent launches. There's also discussion around the mainnet launch date.

JPMorgan Chase & Co. is a financial holding company, which engages in the provision of financial and investment banking services. It focuses on investment banking, financial services for consumers and small businesses, commercial banking, financial transaction processing, and asset management. It operates through the following segments: Consumer and Community Banking (CCB), Commercial and Investment Bank (CIB), Asset and Wealth Management (AWM), and Corporate. The CCB segment originates and services mortgage loans. The CIB segment makes markets and services clients across fixed income, foreign exchange, equities, and commodities. The AWM segment provides initial capital investments in products such as mutual funds and capital invested alongside third-party investors. The Corporate segment manages its liquidity, funding, capital, structural interest rate, and foreign exchange risks. The company was founded in 1799 and is headquartered in New York, NY.

JPMorgan Chase & Co.

JPMorgan Chase & Co

JPMorgan Chase is trending amid mixed sentiment, as discussions range from its ties to controversial figures to its evolving stance on cryptocurrency and potential competition with Bitcoin. The community is actively debating JPMorgan's investment strategies, alleged market manipulation, and the implications of its exploration of blockchain technology and stablecoins. Additionally, some traders are monitoring technical indicators to predict JPM's short-term price movements, while others are discussing potential investigations and regulatory scrutiny.

Alvotech is a biotechnology company, which engages in the development and manufacture of biosimilar medicines. The firm is focusing on the development of its product candidates. It operates through the following geographical segments: Europe, North America, Asia, and Other. The company was founded by Róbert Vilhelm Wessman in 2013 and is headquartered in Luxembourg.

Alvotech

Alvotech ($ALVO) is trending following the announcement of European approval for AVT03, a biosimilar to Prolia and Xgeva, used in bone disease treatment, sparking bullish sentiment. Despite some community concerns about cash flow and previous manufacturing setbacks, the biosimilar's approval and analyst upgrades are fueling optimism. Discussions center on the company's potential in the biosimilar market and strategic partnerships.

Shopify, Inc. is a global commerce company that provides essential internet infrastructure for commerce, offering trusted tools to start, scale, market, and run a retail business of any size. The Company's software enables merchants to run their business across all of their sales channels, including web and mobile storefronts, physical retail locations, social media storefronts and marketplaces. The Shopify platform provides merchants with a single view of their business across all of their sales channels and enables them to manage products and inventory, process orders and payments, fulfill and ship orders, build customer relationships, source products, leverage analytics and reporting and access financing, all from one integrated back office. The company was founded on September 28, 2004 and is headquartered in Ottawa, Canada.

Shopify Inc - Ordinary Shares - Class A (Sub Voting)

Shopify Inc

Shopify is trending as the stock price rises following news of its AI integration with Open AI, which is expected to enhance merchant and customer experiences, with some analysts predicting a significant price target increase. However, some community members are skeptical about the sustainability of Shopify's growth, citing competition and valuation concerns, while others point to the company's strong position in the e-commerce sector and potential for further gains.

Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the Biopharma segment, which comprises commercial operations and research, development and production activities relating to the specialty care, general medicines and vaccines franchises plus support and corporate functions, for all geographical territories. The company was founded in 1973 and is headquartered in Paris, France.

Sanofi - ADR

Sanofi-Aventis

Sanofi-Aventis ($SNY) is trending amid speculation surrounding potential acquisitions, particularly in the MASH and obesity spaces, with $ALT, $GUTS, and $IVA being mentioned as possible targets. Community discussions revolve around the company's pipeline expansion needs and potential partnerships, with some users highlighting data integrity concerns around one of the speculated targets. The broader context involves Sanofi's strategic moves to strengthen its immunology and vaccine portfolio.

mF International Ltd. is a holding company, which engages in the development and provision of financial trading solutions through its subsidiary. It offers real-time mission critical forex, bullion and commodities trading platform solutions, financial value-added services, mobile applications, and financial information for brokers and institutional clients via internet or platform as software as a service. The company was founded by Tai Wai Lam and Chi Weng Tam on June 15, 2022, and is headquartered in Hong Kong.

mF International Ltd - Ordinary Shares - Class A

mF International Ltd

MFI is trending due to its recent $500M private placement aimed at building a Bitcoin Cash treasury, fueling speculation about a potential pivot into crypto equity. Community members are discussing the involvement of a Chinese billionaire and the possibility of MFI becoming a major player in the crypto space. The stock's volatile price action and small float are contributing to the heightened interest.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul><li>According to Telomir, more than 60,000 new cases of Leukemia are diagnosed each year in the U.S.</li><li>Leukemia cells rely heavily on iron as a fuel source, and Telomir-1 in previous research demonstrated the ability to reduce intracellular iron levels.&nbsp;</li><li>The new findings expand on the experimental drug’s previously reported activity in triple-negative breast, pancreatic, and aggressive prostate cancer models.</li></ul>Telomir Pharmaceuticals, Inc. (TELO) said on Friday that its investigational compound Telomir-1 killed aggressive human leukemia (HL60) cells in an in-vitro study.HL60 leukemia cells were treated with Telomir-1, which produced a clear, dose-dependent reduction in viable leukemia cells, indicating strong activity, the company said.Leukemia is a cancer of the blood and bone marrow defined by the uncontrolled growth of abnormal white blood cells.<a href="https://stocktwits.com/symbol/TELO">TELO shares</a> rose 8% at the time of writing.<h2 class="st-heading-2">New Findings</h2>According to Telomir, more than 60,000 new cases of Leukemia are diagnosed each year in the U.S. Leukemia cells rely heavily on iron as a fuel source, and Telomir-1 in previous research demonstrated the ability to reduce intracellular iron levels."The potency observed in HL60 leukemia cells is consistent with the broader biological patterns we have seen throughout Telomir's research…These findings support our scientific framework for evaluating Telomir-1 and inform the ongoing advancement of our overall oncology research program," the company’s chief scientific advisor, Itzchak Angel,<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://telomirpharma.com/#"> said</a>.The new findings expand on the experimental drug’s previously reported activity in triple-negative breast, pancreatic, and aggressive prostate cancer models. The compound is the company’s lead candidate.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around TELO jumped from ‘bearish’ to ‘bullish’ territory over the past 24 hours, while message volume levels rose from ‘extremely low’ to ‘high’ levels.TELO stock is down 66% this year and by 69% over the past 12 months.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/google-ai-infra-chief-must-double-ai-compute-twice-a-year/cLPMFWiREOK">Google AI Infra Chief Says It Must Double AI Compute Twice A Year To Meet Demand: Report</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

In this photo illustration, the Telomir Pharmaceuticals logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

TELO Stock Jumps Pre-market After Early Study Results Show Leukemia Cell Death 

HL60 leukemia cells were treated with Telomir-1, which produced a clear, dose-dependent reduction in viable leukemia cells, indicating strong activity, the company said.

Equity

HL60 leukemia cells were treated with Telomir-1, which produced a clear, dose-dependent reduction in viable leukemia cells, indicating strong activity, the company said.


Shares of Telomir Pharmaceuticals surged nearly 40% in premarket trading on Thursday after the company announced promising new lab results showing that its experimental compound, Telomir-1, can selectively destroy triple-negative breast cancer cells.In laboratory studies using human triple-negative breast cancer (TNBC) cells, researchers observed that as Telomir-1 concentrations increased, more cancer cells stopped growing and eventually died. When iron was reintroduced into the system, the cells regained their ability to survive, pointing to a finding that confirmed Telomir-1’s effects are tied to iron regulation and cellular energy balance.The discovery is significant as TNBC cells are highly dependent on iron to fuel their rapid growth and spread. By cutting off that iron-driven metabolism, Telomir-1 appears to exploit a key vulnerability in these tumors, while normal cells, which process iron differently, remain largely unaffected.Telomir-1 has previously&nbsp;demonstrated the ability to reset abnormal DNA methylation patterns, which are chemical modifications that can alter gene function in preclinical models of cancer and age-related diseases.&nbsp;In this latest study, researchers believe its impact on energy and iron metabolism may stem from its influence on certain enzymes, known as Jumonji domain histone demethylases, which are known to drive tumor aggressiveness and treatment resistance.The study suggests that Telomir-1 may help restore the body’s natural balance, reactivating the normal genetic controls that cancer cells&nbsp;typically shut down to maintain growth.Telomir said it will now seek to use the drug in other hard-to-treat cancers, such as pancreatic and blood cancers, based on these results. The company also expects to soon begin animal studies, a crucial step in the process of seeking FDA approval to begin human trials.On Stocktwits, retail sentiment for Telomir was ‘extremely bullish’ amid ‘extremely high’ message volume.One user said they were surprised the stock hadn’t “gone nuclear” after the breast cancer news broke, adding that they expect it to “go parabolic” in the next session.<stembedurl>https://stocktwits.com/DadiscplinedTrader/message/631612120</stembedurl>Another user commented that the company could eventually attract a buyout offer from a larger pharmaceutical player, suggesting the stock might rise ten to fifteen times, comparing it to past biotech acquisition successes, including that of Provention Bio by Sanofi.<stembedurl>https://stocktwits.com/MarketAttack/message/631581755</stembedurl><a href="https://stocktwits.com/symbol/TELO">Telomir’s stock</a> has declined 60% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Telomir’s stock (TELO) has declined 60% so far in 2025. | Image source: Getty Images

Why Telomir Pharmaceuticals Stock Is Rising 40% Premarket Today

The company said that its experimental drug, Telomir-1, selectively kills aggressive triple-negative breast cancer cells by disrupting their iron-based energy systems.

Shares of Telomir Pharmaceuticals surged during after-hours trading Thursday following the announcement of early laboratory data from research conducted on progeria-affected cells from a young patient.The stock closed at $1.21 on Thursday, then surged 138.8% after hours to $2.89 following the preclinical data.The rare disease, Hutchinson-Gilford Progeria Syndrome (HGPS), emerges from one gene mutation which triggers the accumulation of progerin within the body. The disease affects fewer than 30 children in the U.S.Most start showing symptoms like growth delays and heart problems by age two, and many don’t live past their early teens.&nbsp;The only approved drug, Zokinvy, can add a few years to their lives but doesn’t stop the damage or undo what’s already happened.In the new study, conducted by Smart Assays using cells provided by the Progeria Research Foundation, Telomir-1 improved cell survival in a dose-dependent manner, even under stress conditions.&nbsp;It also reduced levels of reactive oxygen species, a marker of oxidative damage, and corrected iron-induced calcium overload linked to mitochondrial dysfunction.The company stated that these results, observed in actual patient-derived cells, demonstrate that Telomir-1 not only protects cells but also restores critical biological functions.&nbsp;Telomir-1 is designed to regulate metal ions, reduce oxidative stress, restore mitochondrial health, extend telomeres, reverse muscle loss, and reset age-related DNA methylation patterns.CEO Erez Aminov said that the findings support broader potential beyond progeria, including neurodegeneration and metabolic disorders.The results also validated prior preclinical work in animal models, where Telomir-1 extended lifespan and reversed age phenotypes in zebrafish and C. elegans models of Werner syndrome, an adult form of progeria.&nbsp;Telomir is completing IND-enabling studies and is due to meet with the U.S. Food and Drug Administration (FDA) to discuss potential regulatory pathways, including orphan drug designation.On Stocktwits, retail sentiment was ‘extremely bullish’ amid ‘extremely high’ message volume.The Telomir stream on Stocktwits saw a nearly 30% increase in watcher count over the past 24 hours, leading up to late Thursday, with the 24-hour message volume surging up by 8,600%.One user predicted a sharp move, saying Telomir could hit $8–$10 in post-market trading before “a crazy rocket” at the open toward $20 or higher.&nbsp;<stembedurl>https://stocktwits.com/time4themoon/message/621444979</stembedurl>Another user noted the stock’s momentum late in the session, and added that it was “seeing a nice bid going into the extended session close” with expectations to be “jamming in premarket.”<stembedurl>https://stocktwits.com/phijammaslamma/message/621430208</stembedurl><a href="https://stocktwits.com/symbol/TELO">Telomir’s stock</a> has declined 70.3% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Telomir Pharmaceuticals (TELO) said early lab results showed its drug candidate helped restore damaged cells from a child with progeria. (Photo credit: Getty Images)

Telomir Pharma Jumps In After-Hours Trading After Drug Reverses Damage In Progeria Cells; Retail Eyes Bigger Gains

The early lab study used cells from a child with progeria and showed improvements in cell survival, reduced oxidative stress, and restored mitochondrial function, which are key signs of aging. 

Telomir Pharma Jumps In After-Hours Trading After Drug Reverses Damage in Progeria Cells; Retail Eyes Bigger Gains

Telomir Pharmaceuticals' anti-aging expert to present pre-clinical data

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Telomir Pharmaceuticals' Anti-Aging Expert and NYT Bestselling Author Michael F. Roizen, MD, to Present Promising Pre-Clinical Data for Age-Reversal Drug Telomir-1 at the National Press Club in Washington, DC, on April 15, 2024

Telomir's pre-clinical studies demonstrate its lead development product, Telomir-1, elongates telomere caps on human normal embryonic fibroblast cells by stimulating the enzyme telomerase...

UPDATE   Telomir Pharmaceuticals Announces Collaboration with Argenta to Study Osteoarthritis in Canines

Study to determine the efficacy of Telomir-1 on mitigating the clinical signs of osteoarthritis and other age-related diseases This study is believed to be the first and only known study focused on...

Telomir Pharmaceuticals Announces Collaboration with Argenta to Study Osteoarthritis in Canines

Study to determine the efficacy of Telomir-1 on mitigating the clinical signs of osteoarthritis and other age-related diseases This study is believed to be the first and only known study focused...

Telomir Pharmaceuticals Releases New Pre-Clinical Data for Telomir-1  to Be Presented at the Global Longevity Federation Conference in Las Vegas on March 26th

Poster presentation delivers pre-clinical results that demonstrate that its lead development product, Telomir-1, elongates telomere caps on human normal embryonic fibroblast cells The New York Times...

Telomir Pharmaceuticals Uses AI Testing Models to Show its Lead Product Candidate's Potential in DNA Age Reversal Science

Continued work with computer-aided pre-clinical testing shows Telomir-1 has the potential to extend DNA telomeres to reverse age-related conditionsBALTIMORE, March 14, 2024 (GLOBE NEWSWIRE...

Telomir Pharmaceuticals presents preclinical data for Telomir-1

Telomir Pharmaceuticals, Inc. is a pre-clinical-stage pharmaceutical company, which focuses on the development and commercialization of TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic treatment for human stem cells. The firm’s initial focus on treatments to inhibit the production of pro-inflammatory cytokines, such as IL-17, by oral administration of TELOMIR-1 as a therapeutic treatment for stem cells in situ. TELOMIR-1 is under investigation to provide a potential therapeutic intervention against age-related inflammatory conditions such as hemochromatosis, as well as for post-chemotherapy recovery, by interrupting and preventing the IL-17 induced inflammatory pathways that create the systemic imbalance of cellular metals. The company was founded by Christopher C. Chapman Jr. on August 26, 2021 and is headquartered in Miami, FL.

TELO
Telomir Pharmaceuticals Inc

Feed

News

Sentiment

Fundamentals

Info

Latest TELO News

TELOTelomir Pharmaceuticals Inc